Effects of Oral Iron on Postoperative Fatigue Upon Coronary Artery Bypass Graft Patients
Launched by NOVA SCOTIA HEALTH AUTHORITY · Jul 29, 2013
Trial Information
Current as of June 20, 2025
Terminated
Keywords
ClinConnect Summary
Postoperative fatigue (POF) is one of the main complaints in approximately 39-80% of CABG surgery patients. POF can have a significant impact on an individual's quality of life (QoL) and recovery. The objectives are to examine how an oral iron (Feramax®) influences fatigue during early postoperative recovery (at three months) among CABG patients and determine the effects on recovery outcomes (e.g. QoL, functional capacity, anemia, and medication adherence). To achieve these objectives the research will aim to answer the following questions:
1. Is oral iron effective in reducing POF measure...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • • Non-Urgent, first time, coronary artery bypass grafting.
- • American Society of Anesthesia (ASA) physical status II-IV
- • Aged 19 years and older
- • Able to make informed consent by understanding the nature of the participation
- • Able to read and write English to the degree necessary to participate in interviews and questionnaires
- Exclusion Criteria:
- • Had prior median sternotomy surgery
- • A Hemoglobin greater than or equal 120g/L at discharge
- • Previous history of noncompliance with oral medications
- • Received erythropoiesis-stimulating agents (e.g. epoetin alfa and darbepoetin alfa) postoperatively to discharge
- • Allergy to iron History of hematological disorders that are deemed clinically significant as per the investigator's clinical judgment
- • Received Clopidogrel within two days prior to surgery, greater than 81mg of Acetylsalicylic acid 24 hours prior to surgery, or have received "new oral anticoagulants" (e.g. Apixaban, Rivaroxaban, and Dabigatran) within the recommended preoperative exclusion period
- • History of iron metabolism disorders e.g. known iron overload, hemochromatosis, porphyria
- • Chronic fatigue syndrome (a condition that is distinguished from other types of fatigue by fatigue lasting more than six months and has at least four other symptoms (e.g. sleep disturbances, headaches, joint pain, and concentration difficulties) that could contribute to increased fatigue (Afari \& Buchwald, 2003)).
- • A serum transferrin saturation of more than 50% at discharge
- • History of Fibromyalgia
- • Current diagnosis of depressive disorder
- • History of Hypothyroidism includes uncontrolled thyroid disease (abnormal Thyroid Stimulating Hormone (TSH) or Thyroxine (T4) at screening visit) as per the Investigator's clinical judgment
- • Patient taking iron supplementation ≤ 60 days before surgery and in the postoperative period
- • Any other unstable conditions as per the Investigator's clinical judgment
- • Contraindications to the six-minute walk test
- • Physical disability preventing safe performance
- • Resting heart rate \> 120 beats/min 10 min after rest (relative contraindications)
- • Systolic blood pressure \>180mm ± Diastolic blood pressure \> 100mm Hg (relative contraindications)
- • Resting Sp02 \<85% on room air or on a prescribed level of supplemental oxygen
About Nova Scotia Health Authority
The Nova Scotia Health Authority (NSHA) is a leading healthcare organization dedicated to enhancing the health and well-being of individuals and communities across Nova Scotia, Canada. As the largest provider of health services in the province, NSHA is committed to advancing clinical research and innovation through rigorous clinical trials that aim to improve patient care and outcomes. With a focus on collaboration, NSHA engages healthcare professionals, researchers, and patients to address pressing health challenges and contribute to the global body of medical knowledge. By fostering a culture of evidence-based practice and continual improvement, NSHA plays a pivotal role in shaping the future of healthcare delivery in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Halifax, Nova Scotia, Canada
Patients applied
Trial Officials
Blaine Kent, MD
Principal Investigator
Capital Health, Canada
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials